CN102614461A - 快速缓解心绞痛的喷雾剂及其制备方法 - Google Patents
快速缓解心绞痛的喷雾剂及其制备方法 Download PDFInfo
- Publication number
- CN102614461A CN102614461A CN2012100912234A CN201210091223A CN102614461A CN 102614461 A CN102614461 A CN 102614461A CN 2012100912234 A CN2012100912234 A CN 2012100912234A CN 201210091223 A CN201210091223 A CN 201210091223A CN 102614461 A CN102614461 A CN 102614461A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- preparing
- spray
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000007921 spray Substances 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 54
- 239000000654 additive Substances 0.000 claims abstract description 26
- 230000000996 additive effect Effects 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000000605 extraction Methods 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 25
- 239000002994 raw material Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 241000972155 Moschus Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 11
- 244000153234 Hibiscus abelmoschus Species 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 208000029078 coronary artery disease Diseases 0.000 description 9
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 206010025482 malaise Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- -1 anti-platelet agent Substances 0.000 description 6
- 230000036770 blood supply Effects 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 208000007718 Stable Angina Diseases 0.000 description 5
- 208000007814 Unstable Angina Diseases 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 206010042772 syncope Diseases 0.000 description 5
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 4
- 208000026758 coronary atherosclerosis Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 235000015511 Liquidambar orientalis Nutrition 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 244000173166 Pyrus ussuriensis Species 0.000 description 2
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000010513 Stupor Diseases 0.000 description 2
- 241000736148 Styrax Species 0.000 description 2
- 239000004870 Styrax Substances 0.000 description 2
- 235000000126 Styrax benzoin Nutrition 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010051124 Hyperfibrinogenaemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241001060310 Styracaceae Species 0.000 description 1
- 235000001361 Styrax officinalis Nutrition 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210091223.4A CN102614461B (zh) | 2012-03-31 | 2012-03-31 | 快速缓解心绞痛的喷雾剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210091223.4A CN102614461B (zh) | 2012-03-31 | 2012-03-31 | 快速缓解心绞痛的喷雾剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102614461A true CN102614461A (zh) | 2012-08-01 |
CN102614461B CN102614461B (zh) | 2014-03-12 |
Family
ID=46554909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210091223.4A Expired - Fee Related CN102614461B (zh) | 2012-03-31 | 2012-03-31 | 快速缓解心绞痛的喷雾剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102614461B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104225470A (zh) * | 2014-09-10 | 2014-12-24 | 柏伟伟 | 一种缓解心绞痛的中药组合物及其制备方法 |
CN105920528A (zh) * | 2016-05-26 | 2016-09-07 | 孙明香 | 一种快速缓解心绞痛的中药喷雾剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1239668A (zh) * | 1998-06-19 | 1999-12-29 | 谢天方 | 心脑通脉口服液及其制备方法 |
CN101085013A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 含丹参、红花、黄芪和降香油的中药组合物及其制剂 |
CN101099847A (zh) * | 2006-07-07 | 2008-01-09 | 黄振华 | 一种用于心脑血管疾病的药物 |
CN101164607A (zh) * | 2007-09-29 | 2008-04-23 | 李生 | 治疗心悸不适、动辄气促的中药 |
-
2012
- 2012-03-31 CN CN201210091223.4A patent/CN102614461B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1239668A (zh) * | 1998-06-19 | 1999-12-29 | 谢天方 | 心脑通脉口服液及其制备方法 |
CN101085013A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 含丹参、红花、黄芪和降香油的中药组合物及其制剂 |
CN101099847A (zh) * | 2006-07-07 | 2008-01-09 | 黄振华 | 一种用于心脑血管疾病的药物 |
CN101164607A (zh) * | 2007-09-29 | 2008-04-23 | 李生 | 治疗心悸不适、动辄气促的中药 |
Non-Patent Citations (3)
Title |
---|
何敬华: "益心方治疗冠心病86例疗效观察", 《医学创新研究》 * |
李俊等: "益心方治疗冠心病稳定型心绞痛40例临床研究", 《辽宁中医杂志》 * |
李景鹤: "益气养阴活血方治疗冠心病50例", 《河南中医》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104225470A (zh) * | 2014-09-10 | 2014-12-24 | 柏伟伟 | 一种缓解心绞痛的中药组合物及其制备方法 |
CN105920528A (zh) * | 2016-05-26 | 2016-09-07 | 孙明香 | 一种快速缓解心绞痛的中药喷雾剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102614461B (zh) | 2014-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104784673B (zh) | 一种用于小儿腹泻的中药脐贴 | |
CN103919910B (zh) | 一种治疗冠心病的药物 | |
CN103182012A (zh) | 一种治疗缺血性脑中风的药物及其制备方法 | |
CN102614461B (zh) | 快速缓解心绞痛的喷雾剂及其制备方法 | |
CN102614462B (zh) | 治疗冠心病的中药组合物及其制备方法 | |
CN102614460B (zh) | 治疗心肌梗塞的中药组合物及其制备方法 | |
CN102614459B (zh) | 快速治疗心肌缺血的中药喷雾剂及其制备方法 | |
CN103285328B (zh) | 治疗冠心病的中药组合物胶囊的制备方法 | |
CN102266481B (zh) | 一种治疗慢性脑供血不足的中药制剂 | |
CN102091163B (zh) | 一种治疗糖尿病性心脏病的中药组合物 | |
CN102125604B (zh) | 治疗产后缺乳的中药制剂 | |
CN103223107A (zh) | 一种用于调节血脂血压的中药及其制备工艺 | |
CN103285327B (zh) | 治疗冠心病的中药组合物片剂及其制备方法 | |
CN103330911B (zh) | 治疗冠心病的中药组合物粉剂及其制备方法 | |
CN102727738A (zh) | 用于治疗慢性阻塞性肺疾病的中药组合物及其制备方法 | |
CN102961540A (zh) | 一种治疗冠心病的药物及其制备方法 | |
CN105079586A (zh) | 一种治疗高血压的中药组合物 | |
CN104225470A (zh) | 一种缓解心绞痛的中药组合物及其制备方法 | |
CN106728828A (zh) | 一种治疗冠心病的中药制剂及其制备工艺 | |
CN105288143A (zh) | 一种治疗哮喘的中药组合物 | |
CN104825735A (zh) | 补肾保健药酒 | |
CN103157068B (zh) | 治疗心肌梗塞的中药组合物粉剂及其制备方法 | |
CN105434903A (zh) | 一种治疗冠心病的中药制剂 | |
CN103142941B (zh) | 治疗心肌梗塞的中药组合物胶囊及其制备方法 | |
CN103142942B (zh) | 治疗心肌梗塞的中药组合物片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CHEN FANG Free format text: FORMER OWNER: LI HAOCHENG Effective date: 20131225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Fang Inventor before: Li Haocheng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250014 JINAN, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: LI HAOCHENG TO: CHEN FANG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20131225 Address after: 266200, No. 1, building 16, 2 middle street, kiln head, Jimo, Shandong, Qingdao Applicant after: Chen Fang Address before: 250014 Shandong Institute of politics and law, No. 63 Jiefang East Road, Lixia District, Shandong, Ji'nan Applicant before: Li Haocheng |
|
ASS | Succession or assignment of patent right |
Owner name: WAN WEI Free format text: FORMER OWNER: CHEN FANG Effective date: 20140106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wan Wei Inventor after: Liu Meiling Inventor after: Lu Chunni Inventor before: Chen Fang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 266000 QINGDAO, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: CHEN FANG TO: WAN WEI LIU MEILING LU CHUNNI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140106 Address after: 266000 Shandong city of Qingdao Province Economic and Technological Development Zone Xuejiadao demonstration area of the first floor of a unit Applicant after: Wan Wei Address before: 266200, No. 1, building 16, 2 middle street, kiln head, Jimo, Shandong, Qingdao Applicant before: Chen Fang |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIMEN JIANGHAI CONSTRUCTION INVESTMENT CO., LTD. Free format text: FORMER OWNER: WAN WEI Effective date: 20140625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266000 QINGDAO, SHANDONG PROVINCE TO: 226100 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140625 Address after: 226100, 999, Guangzhou Road, Haimen, Jiangsu, Nantong Patentee after: HAIMEN JIANGHAI CONSTRUCTION INVESTMENT CO., LTD. Address before: 266000 Shandong city of Qingdao Province Economic and Technological Development Zone Xuejiadao demonstration area of the first floor of a unit Patentee before: Wan Wei |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140312 Termination date: 20170331 |